Abstract

The experiments were carried out on 46 white laboratory male rats Wistar with a body weight of 250–280 g. Animals were daily administered intraperitoneally for 28 days with bromocriptine at a dose of 1 mg/kg and, as a control, physiological saline. In animals treated with bromocriptine, an accumulation of autoantibodies in blood serum and in brain tissue to neuroreceptors was found compared to control animals: NMDA (subunits NR1, NR2A, NR2B) and to dopamine receptors of the first and second types (DR1 and DR2). At the same time, the level of autoantibodies in the brain was significantly lower. High levels of autoantibodies were detected after 2 and 4 weeks from the start of immunization of animals. After completion of the chronic administration of bromocriptine, a high level of autoantibodies persisted 3 and 7 days after the last administration of the drug. 14 days after completion of the injections, the level of autoantibodies in the blood and brain decreased significantly. In the group of rats in which autoantibodies were determined 4 weeks after completion of injections, their level did not differ from the values in control animals. An increase of autoantibodies to the S100B protein was found. The levels of autoantibodies to the S100B protein in the blood serum had a positive moderate relationship with the content of autoantibodies to NR2A, NR2B and DR2 in the brain tissue. At the same time, there were no correlations with the levels of AAT to neuroreceptors in the blood.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.